Centessa (CNTA) Insider Exercise and Planned Sale of 6,000 Shares

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (CNTA) filing a Form 144 notifies a proposed sale of 6,000 common shares to be offered through UBS Financial Services on Nasdaq with an aggregate market value of $103,380.00. The filer reports those shares were acquired the same day, 08/15/2025, by exercising stock options and paid in cash.

The filing also discloses prior sales by the same person, Iqbal Hussain: 12,000 shares sold on 06/24/2025 for $168,218.40 and 6,000 shares sold on 07/15/2025 for $89,566.80. The notice affirms no undisclosed material nonpublic information applies to the seller.

Insights

Securities Analyst

TL;DR Insider exercised options and is selling a small block of shares; transactions are routine and immaterial to company capitalization.

The 6,000-share proposed sale represents a very small fraction of the issuer's reported outstanding shares (134,073,436), so dilution or market impact is negligible. The acquisition via option exercise and immediate planned sale is a common liquidity action. Prior sales totaling 18,000 shares in the past three months show ongoing portfolio cashing but are minor relative to outstanding shares. No financial results or governance changes are disclosed.

Corporate Governance Expert

TL;DR The Form 144 is a standard compliance notice tied to option exercise and planned resale; it includes the seller's required certifications.

The filer certifies absence of undisclosed material information and, if applicable, reliance on a trading plan is noted though no plan date is provided. The record lists broker, acquisition method, payment type, and recent sales history, fulfilling disclosure obligations. There are no governance issues, regulatory actions, or material events disclosed in this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	6000	103380.00	134073436	08/15/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Exercise of Stock Options	Issuer			6000	08/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	06/24/2025	12000	168218.40
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 X0 WA14 2D	Common	07/15/2025	6000	89566.80

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for CNTA disclose about the proposed sale?

It discloses a proposed sale of 6,000 common shares through UBS on Nasdaq with aggregate market value $103,380.00.

How were the shares being sold on 08/15/2025 acquired?

The shares were acquired on 08/15/2025 by exercise of stock options and paid for in cash.

Who is the seller named in recent transactions?

The seller named for recent sales is Iqbal Hussain, who sold 12,000 shares on 06/24/2025 and 6,000 shares on 07/15/2025.

How many outstanding shares does Centessa report in the filing?

The filing lists 134,073,436 shares outstanding.

Does the filer attest to possession of undisclosed material information?

Yes. By signing the notice the filer represents they do not know any material adverse information about the issuer that is not public.